"Endpuff" is the first smoking cessation aid officially approved by the Ministry of Food and Drug Safety (MFDS) of South Korea as a "Smoking Habit Improvement Supplement." Unlike traditional nicotine replacement therapies, Endpuff is the world's first vaping-based smoking habit improvement supplement that contains no nicotine. It is the first product in South Korea to apply for MFDS approval in the category of "Smoking Habit Improvement Supplement."
To ensure the safety and efficacy of its ingredients, Endpuff underwent rigorous evaluation and testing in collaboration with the Korea Institute of Toxicology (KIT) and the Korea Conformity Laboratories (KCL). Together, they developed standards and methods for gas inhalation toxicity testing, along with the necessary equipment. Over the course of nine years, the product's safety and stability were confirmed through gas inhalation toxicity tests, IRB clinical trials, and micronucleus tests, ultimately certifying its effectiveness.
Endpuff addresses the issues associated with traditional nicotine replacement therapies, such as nicotine dependence and both mental and physical side effects. It can be used alongside other smoking cessation products, allowing for a more structured and comprehensive quit plan. By alleviating the desire to smoke in various situations, Endpuff helps reduce psychological and emotional stress, which are significant factors in smoking relapse.
Furthermore, by preventing secondhand smoke and odors typically associated with smoking or combustion-based smoking cessation products, Endpuff contributes to the improvement of public health.